Azmasol Bexicap (DPI) Inhaler
Azmasol Bexicap (DPI) Inhaler is manufactured by Beximco Pharmaceuticals Ltd. Azmasol Bexicap (DPI) Inhaler contains 200 mcg/bexicap Salbutamol (Inhalation Aerosol). It is Short-acting selective β2-adrenoceptor stimulants class drug.
Salbutamol is a relatively selective ß2 adrenoreceptor stimulant. It is more specific than both isoprenaline and orciprenaline for adrenergic ß2 receptors. Salbutamol is a sympathomimetic agent which has a highly selective action on ß adrenergic receptors in bronchial muscle. It provides short acting (4 to 6 hour) bronchodilation with fast onset (within 5 minutes) in reversible airway obstruction. ß2 adrenoceptor agonist is used in the treatment of asthma and other forms of diffuse reversible airways obstruction.
Salbutamol inhaler is used for the treatment and prophylaxis of bronchial asthma and for the treatment of reversible airways obstruction associated with bronchitis and emphysema.
Salbutamol inhaler may be used to relieve attacks of acute dyspnoea and may also be taken prophylactically before exertion or to prevent exercise-induced asthma.
Salbutamol inhaler is suitable for treating bronchospasm in patients with coexisting heart disease or hypertension, including those taking beta blockers, because of its selective action on the bronchial receptors and lack of effects on the cardiovascular system. At therapeutic levels, it has little effect on cardiac receptors.
|Brand Name:||Azmasol Bexicap (DPI)|
|Generic:||Salbutamol (Inhalation Aerosol)|
|Therapeutic Class:||Short-acting selective β2-adrenoceptor stimulants|
|Manufacturer:||Beximco Pharmaceuticals Ltd|
|Last Updated:||November 21, 2020 at 6:15 pm|
Table Of contents
Azmasol Bexicap (DPI) contains Salbutamol (Inhalation Aerosol) 200 mcg/bexicap. Azmasol Bexicap (DPI) Dosage:
Salbutamol inhaler is administered by the inhaled route only. Shake Salbutamol Inhaler well before each spray. As there may be adverse effects associated with excessive dosing, the dosage or frequency of administration should only be increased on medical advice.
- For the relief of acute bronchospasm and for managing intermittent episodes of asthma: One or two puffs as a single dose
- For chronic maintenance or prophylactic therapy: Two puffs three or four times daily
- For prevention of exercise induced bronchospasm: Two puffs before exertion
- For prevention of exercise induced bronchospasm: Two puffs should be taken at least 15 minutes before exertion
- For the relief of acute bronchospasm, management of episodic asthma and for prevention of exercise induced bronchospasm: One puff may be administered as a single dose. Only for the use of medical professionals
- For routine maintenance and prophylaxis: One puff three or four times daily, increasing if necessary to two puffs three or four times daily
Elderly: The dosage is the same as that for adults.
Mild tremor and headache have been rarely reported. These usually disappear with continuous treatment. There have been very rare reports of transient muscle cramp. Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse have been reported very rarely. As with other inhalation therapy, the potential for paradoxical bronchospasm should be kept in mind. If it occurs, the preparation should be discontinued immediately and alternative therapy should be instituted.
Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis. In the event of previously effective dose of salbuatmol inhaler failing to give relief for at least three hours, the patient should be advised to seek medical advice in order that any necessary additional steps may be taken.
The management of asthma should normally a stepwise programme, and patient response should be monitored clinically and by lung function test. Increasing use of short acting inhaled agonists to control symptoms indicates deterioration of asthma control. Under these conditions, the patient’s therapy plan should be reassessed. Sudden and progressive deterioration in asthma control is potentially life threatening and consideration should be given to starting or increasing corticosteroid therapy. In patients considered at risk, daily peak flow monitoring may be instituted. Patients inhaler techinique should be checked to make sure that aerosl actuation is synchronized with inspiration of breath for optimum delivery of the drugs to the lungs.
Salbutamol should be administered with caution to patients being treated with monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants, since the action of salbutamol on the vascular system may be potentiated. The effects of salbutamol are inhibited by beta-2 antagonists such as propranolol. Other sympathomimetic aerosol bronchodilator should not be used concomitantly with salbutamol. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects. Treatment with diuretics may augment the hypokalemia that occurs with large doses of salbutamol.
Pregnancy Lactation use
Salbutamol is known to cross the placental barrier in humans. Safety for use in pregnancy has not been demonstrated, therefore the drug should not be used in pregnant women, or those likely to become pregnant, unless the expected benefit outweighs any potential risk. Oral administration of salbutamol to rats and rabbits during pregnancy showed no teratogenic effects in offspring, but evidence of retardation of fetal development was recorded in an inhalational teratology study in rabbits at an estimated dose of 149 μg/kg/day. Although intravenous salbutamol and occasionally salbutamol tablets are used in the management of uncomplicated premature labour, Salbutamol presentations should not be used for threatened abortion during the first or second trimesters of pregnancy.
Intravenous salbutamol is contra-indicated in cases of ante-partum haemorrhage because of the risk of further haemorrhage from an atonic uterus and there is the risk of the same problem arising inadvertently in asthmatics using salbutamol. Profuse uterine bleeding following spontaneous abortion has been reported after the use of salbutamol. Special care is required in pregnant diabetic women. As salbutamol is probably secreted in breast milk, its use in nursing mothers is not recommended unless the expected benefit to the mother is greater than any possible risk to the infant.
Salbuatmol inhaler is contraindicated in patients with a history of hypersensitivity to any of its components. Although intravenous salbutamol, and occasionally salbutamol tablets, is used in the management of premature labour uncomplicated by conditions such as placenta praevia, ante-partum haemorrhage or toxaemia of pregnancy, salbutamol inhaler preparations are not appropriate for managing premature labour. Salbutamol preparation should not be used for threatened abortion during the first or second trimesters of pregnancy.
As with all sympathomimetic aerosol medications, cardiac arrest and even death may be associated with abuse. The preferred antidote for overdose with salbutamol inhaler is cardioselective beta-blocker, such as metoprolol tartarate. But b-blockers should be used with caution in patients with a history of bronchospasm. Dialysis is not appropriate treatment for overdose of salbutamol inhalation aerosol.
Interaction with other Medicine
Do not puncture, break or incinerate pressurized canister even when apparently empty. Avoid storage in direct sunlight or heat. Store below 30°C. Keep away from eyes. Keep away from children.